Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Second mitochondrial activator of caspase (Smac)-mimetic compounds (SMCs) and oncolytic viruses (OVs) are developed for direct cancer cell killing.
• Both therapies modulate host immune responses, suggesting potential synergistic effects on anticancer immunity.

Purpose of the Study:

• To investigate the combined effects of SMC and OV therapies on anticancer T-cell immunity.
• To elucidate the distinct mechanisms by which each therapy contributes to synergistic immune responses.

Main Methods:

• Treatment of aggressive mouse cancer models with Smac-mimetic compound LCL161 and oncolytic virus VSVΔM51, individually and in combination.
• Analysis of CD8+ T-cell responses, including T-cell exhaustion, polarization of tumor-associated macrophages, T-cell accumulation in tumors, and T-cell activation in tumor-draining lymph nodes.

Main Results:

• SMC treatment (LCL161) reinvigorates exhausted CD8+ T cells by promoting M1-like polarization of tumor-associated macrophages.
• OV treatment (VSVΔM51) enhances CD8+ T-cell accumulation within tumors and activation in lymph nodes.
• Combination therapy of LCL161 and VSVΔM51 demonstrates synergistic CD8+ T-cell-mediated tumor control in aggressive mouse cancer models.

Conclusions:

• Combined SMC and OV therapies synergize to promote anticancer T-cell immunity through distinct yet complementary mechanisms.
• This combination approach represents a promising strategy for enhancing anti-tumor immune responses in clinical settings.